Allakos Inc ALLK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALLK is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $1.28
- Day Range
- $1.23–1.27
- 52-Week Range
- $0.98–5.64
- Bid/Ask
- $1.23 / $1.24
- Market Cap
- $109.35 Mil
- Volume/Avg
- 52,768 / 482,065
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 131
- Website
- https://www.allakos.com
Comparables
Valuation
|
Metric
|
ALLK
|
CTIC
|
VOR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.09 | — | 0.69 |
Price/Sales | — | 14.71 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALLK
|
CTIC
|
VOR
|
|---|---|---|---|
Quick Ratio | 3.88 | 1.20 | 8.13 |
Current Ratio | 4.11 | 1.27 | 8.46 |
Interest Coverage | — | −3.20 | — |
Quick Ratio
ALLK
CTIC
VOR
Profitability
|
Metric
|
ALLK
|
CTIC
|
VOR
|
|---|---|---|---|
Return on Assets (Normalized) | −54.70% | −46.52% | −48.29% |
Return on Equity (Normalized) | −73.03% | — | −61.06% |
Return on Invested Capital (Normalized) | −64.58% | −143.40% | −54.20% |
Return on Assets
ALLK
CTIC
VOR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Bpcgzdnl | Cccqgb | $124.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mpjskwzm | Vlphvn | $111.3 Bil | |||
| Moderna Inc
MRNA
| Bynbvnd | Htjjk | $56.9 Bil | |||
| BioNTech SE ADR
BNTX
| Gkxncmmb | Jyhnx | $24.2 Bil | |||
| argenx SE ADR
ARGX
| Rmrwdhyhd | Ccxx | $22.5 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Sjgqwtlv | Qrhwm | $20.1 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lvvnvrg | Wrzmvb | $16.1 Bil | |||
| Incyte Corp
INCY
| Jkrxtly | Wjqlkl | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Mjgtjhkrg | Hyvxbw | $12.4 Bil | |||
| United Therapeutics Corp
UTHR
| Sqzmvcxxh | Rfzqf | $12.2 Bil |